This brand name is authorized in Nigeria.
The drug METAP contains one active pharmaceutical ingredient (API):
1
|
UNII
TH25PD4CCB - METOPROLOL SUCCINATE
|
|
Metoprolol is a cardioselective beta-adrenergic blocking agent. It has a relatively greater blocking effect on beta1-receptors (ie those mediating adrenergic stimulation of heart rate and contractility and release of free fatty acids from fat stores) than on beta2-receptors, which are chiefly involved in broncho and vasodilation. |
|
This drug has been approved in Nigeria as follows:
| Identifier | Form | Presentation | Description | Approval |
|---|---|---|---|---|
| B4-0555 | Tablet | Metap-Xl 50 Tablets TAB 50 mg 3 x 10 (in blister packs) | Tablet White, circular, biconvex, film coated tablets with "Micro" engraved on both sides | 26/08/2021 |
| B4-0556 | Tablet | Metap-Xl 25 Tablets TAB 25 mg 3 x 10's (in blisters) | Tablet Yellow colored, circular, biconvex, film coated tablets with "Micro"’ engraved on both sides | 26/08/2021 |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| NG | Registered Drug Product Database | B4-0555, B4-0556 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.